.png){kind=icon}
Return
Harnessing off-target effects
.png){kind=icon}
PRE
AI
DOI：10.1038/nchembio.2519.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action.
Keywords:
CHEMOTHERAPY
CERITINIB
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
13.7
Papers:
4.8K
Citations:
3.3W
Organization
Cited Papers
ShareSaveShareSaveShareSaveSWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group..png)
BMJ
OAAI
BMJIF0
OAAIShareSavePolypharmacology-based ceritinib repurposing using integrated functional proteomicsNATURE CHEMICAL BIOLOGYOAAI
NATURE CHEMICAL BIOLOGYIF13.7
OAAIShareSaveShareSaveShareSave no more
no more